Metabolic engineering generates a transgene-free safety switch for cell therapy
- 13 July 2020
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 38 (12) , 1441-1450
Abstract
Safeguard mechanisms can ameliorate the potential risks associated with cell therapies but currently rely on the introduction of transgenes. This limits their application owing to immunogenicity or transgene silencing. We aimed to create a control mechanism for human cells that is not mediated by a transgene. Using genome editing methods, we disrupt uridine monophosphate synthetase (UMPS) in the pyrimidine de novo synthesis pathway in cell lines, pluripotent cells and primary human T cells. We show that this makes proliferation dependent on external uridine and enables us to control cell growth by modulating the uridine supply, both in vitro and in vivo after transplantation in xenograft models. Additionally, disrupting this pathway creates resistance to 5-fluoroorotic acid, which enables positive selection of UMPS-knockout cells. We envision that this approach will add an additional level of safety to cell therapies and therefore enable the development of approaches with higher risks, especially those that are intended for limited treatment durations.Keywords
This publication has 67 references indexed in Scilit:
- Inducible Apoptosis as a Safety Switch for Adoptive Cell TherapyNew England Journal of Medicine, 2011
- From DNA to Targeted Therapeutics: Bringing Synthetic Biology to the ClinicScience Translational Medicine, 2011
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cellsBlood, 2011
- A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacyJournal of Clinical Investigation, 2011
- Translating the Lessons From Gene Therapy to the Development of Regenerative MedicineMolecular Therapy, 2011
- Enhanced Uridine Bioavailability Following Administration of a Triacetyluridine-Rich Nutritional SupplementPLOS ONE, 2011
- The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignanciesBlood, 2007
- Tumor cells escape suicide gene therapy by genetic and epigenetic instabilityBlood, 2004
- Chimeric Nucleases Stimulate Gene Targeting in Human CellsScience, 2003
- Hereditary orotic aciduria: Long-term therapy with uridine and a trial of uracilThe Journal of Pediatrics, 1969